![Partnership to Accelerate SARS-CoV-2 Variant Identification in the US](https://www.g2intelligence.com/wp-content/uploads/2022/03/mar23-2022-News-COVIDVariants-NIH-Thermo-iStock-1800x1250-1.jpg)
![Partnership to Accelerate SARS-CoV-2 Variant Identification in the US](https://www.g2intelligence.com/wp-content/uploads/2022/03/mar23-2022-News-COVIDVariants-NIH-Thermo-iStock-1800x1250-1.jpg)
![FDA Releases Recommendations for Safe Use of At-Home COVID-19 Tests](https://www.g2intelligence.com/wp-content/uploads/2022/03/Mar23-2022.News_.CovidHomeTest-iStock-1800x1250-1.jpg)
FDA Releases Recommendations for Safe Use of At-Home COVID-19 Tests
On March 18, the U.S. Food and Drug Administration (FDA) released a Safety Communication about the dangers of improperly used FDA authorized at-home COVID-19 tests. The agency also reminded the public that these tests should be safely stored away from children and...![Saliva Testing for COVID-19 Quicker, Safer than Nasal Swabs](https://www.g2intelligence.com/wp-content/uploads/2022/03/Mar21-2022-ACMB-COVID-19-Saliva-Tests-iStock-1800x1250-1.jpg)
Saliva Testing for COVID-19 Quicker, Safer than Nasal Swabs
WASHINGTON, DC — Genetic testing of saliva samples identifies the SARS-CoV-2 virus more quickly than testing of nasal swabs, according to research published March 21 in Microbiology Spectrum, a journal of the American Society for Microbiology. “That is important...![Omicron Drives New Surge in National Telehealth Utilization](https://www.g2intelligence.com/wp-content/uploads/2022/03/April22.DTET_.TelehealthUtiliz-iStock-1800x1250-1.jpg)
Omicron Drives New Surge in National Telehealth Utilization
...
![FDA Orders LuSys and Celltrion to Recall Unauthorized COVID-19 Rapid Tests](https://www.g2intelligence.com/wp-content/uploads/2022/03/Mar17-2022-FDA-LuSys-Celltrion-Crackdown-iStock-1800x1250-1.jpg)